Julie A. Johnson, PharmD
Julie A. Johnson, PharmD, FCCP, BCPS
Dean and Distinguished Professor
University of Florida College of Pharmacy
Department of Pharmacotherapy and Translational Research
OFFICE: HPNP 4332
|BS||Ohio State University||Pharmacy|
|PharmD||University of Texas Austin & University of Texas||Pharmacy|
|Post-Doctoral Fellowship||Ohio State University||Cardiovascular Pharmacology/Pharmacokinetics|
Julie A. Johnson, Pharm.D., is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/pharmacokinetics at Ohio State.
Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. She is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 290 peer reviewed publications and nearly $50 million in research funding as principal investigator. In 2015, 2016, 2017 she was named a Thomson Reuters (now Clarivate Analytics) Highly Cited Scientist in Pharmacology and Toxicology, and in 2018 in the Cross Discipline category, indicating she is in the top 1% of the most highly cited scientists in the field globally.
Johnson has served on the Nonprescription Drugs Advisory Committee of the FDA, the XNDA Study Section at NIH, and in numerous scientific capacities with NIH’s NHLBI. She has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology (ACCP-Pharmacology). Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including teaching awards from both the University of Tennessee (1996) and the University of Florida (2001); the Ohio State University Alumni Association William Oxley Thompson Award for early career achievement (1997), Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award (2009) and Russell R Miller Award for Contributions to the Literature (2010), both from ACCP, the Southeastern Universities Research Association Distinguished Scientist Award (2015); AACP Volwiler Research Achievement Award (2016), the ACCP-Pharmacology Distinguished Scientist Award (2019), and ACCP Paul Parker Medal (2019), among others.
Johnson’s research focus is cardiovascular drug pharmacogenomics, and disease-gene associations that may be relevant to pharmacogenomics, and the influence of race/ethnicity on drug response and pharmacogenomics. The majority of her research centers around efforts in hypertension, heart failure, with a primary focus on proteins that are drug targets and the impact of their genetic polymorphisms on drug response and disease. Her research has been continuously funded by the National Institutes of Health or the American Heart Association since 1990. She is a member of the NIH Pharmacogenetics Research Network, with a project focused on pharmacogenomics of antihypertensive drugs.
Full Publication List via PubMed
Please click here for a list of Julie Johnson’s industry relationships.